Lineage Cell Therapeutics ↗
Biotechnology: Biological Products (No Diagnostic Substances) company
Key Metrics of Lineage Cell Therapeutics
Revenue$8.9M▼ 39.2% YoYFY 2023
Operating income−$24.7M▼ 9.8% YoY
Net profit−$21.5M▲ 18.2% YoY
Shareholders' equity$63.4M
Market cap$255MLCTX · $1.01
Competitors10identified
About Lineage Cell Therapeutics
Sectors
Company details
- Website
- lineagecell.com
- Listed
- NYSE: LCTX
Operational Areas of Lineage Cell Therapeutics
Pharmaceuticals & Healthcare›Biotechnology & Vaccines
Company summary
Legal nameLineage Cell Therapeutics Inc.
TickerLCTX
ExchangeNYSE
CountryUnited States
SEC CIK0000876343
Listed since—
IndustryBiotechnology: Biological Products (No Diagnostic Substances)
SectorPharmaceuticals & Healthcare · Biotechnology & Vaccines
Websitehttps://www.lineagecell.com
US market & SEC filings
LCTX · NYSE · SEC CIK 0000876343
Last price · 03 Nov 2026
$1.01
+1.00%
Market cap$255M
P/E—On FY 2023 diluted EPS
Volume1,722,936
SectorHealth CareBiotechnology: Biological Products (No Diagnostic Substances)
Country · IPOUnited States
LCTX share price
Premium
Annual results (SEC EDGAR)
Revenue, operating income, net income, EPS, cash flow, assets, liabilities, equity and debt for every year filed with the SEC are part of the premium plan.
Sign in to continue See plans & pricingVendor checks & payment capacity
Sign in with access to company financials to review vendor evidence.
Registered office and contact
Registered officeCarlsbad
GSTIN—
Email—
Websitehttps://www.lineagecell.com
Members / shareholders—
Directors and key people
Directors are read from the MGT-7 annual return and AOC-4 signatories.
Competitors of Lineage Cell Therapeutics
Competitors10identified
Countries1most in United States
Top competitors by location
| Company | Description | Domain | Founded | Location |
|---|---|---|---|---|
| Part of Vertex Pharmaceuticals. | vrtx.com | 1991 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | modernatx.com | 2018 | United States | |
 Becton Dickinson |
Biotechnology & Vaccines · Pharmaceuticals & Healthcare | bd.com | — | United States |
| Part of Illumina. | illumina.com | 2000 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | guardanthealth.com | 2018 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | exelixis.com | 2000 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | revvity.com | — | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | neurocrine.com | 1996 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | biomarin.com | 1999 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | bio-rad.com | 1980 | United States |
Charges (secured borrowings)
0 registered charges. Lenders, amounts and dates are part of the premium plan.
Statutory auditors
Auditors are read from the AOC-4 auditor's report section.
Business activities and related parties
biotechnology
Filings
No filings on record yet.